Market Research Logo

Botanical and Plant-derived Drugs: Global Markets

Botanical and Plant-derived Drugs: Global Markets

The global market for botanical and plant-derived drugs will grow from $29.4 billion in 2017 to around $39.6 billion by 2022 with a compound annual growth rate (CAGR) of 6.1% for the period of 2017-2022.

The plant-derived drugs market will grow from $29.3 billion in 2017 to around $39.2 billion by 2022 with a CAGR of 5.9%.

The Botanical drugs market will grow from $57.0 million in 2017 to $425 million by 2022 with a CAGR of 49.5%.


Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Trends and Drivers for Botanical Drug Development
Chapter 3 Market and Technology Background
Brief History of Plant-Derived Medicines
Opportunity Lies Beyond What Is Known
Getting Started
Key Drivers
Key Challenges
U.S. Government Investment
Industry Investment
Nutrition Science Partners Ltd. (Nestlé Health): A Case Study
Botanical Drugs Defined
Understanding the Regulatory Process
Investigational New Drug Applications
Clinical Trials
New Drug Application
The First and Second U.S. Approved Botanical Drug
Veregen (Chinese Green Tea Catechins)
Mytesi, Formerly Fulyzaq (Crofelemer)
Botanical Candidates in the Pipeline
Samital
Danshen Dripping Pill (Cardiotonic Pill)
EISO (East Indian Sandalwood Oil)
Microbio and WH-1, MB-6 and OB318
A Growing Pipeline
Overall Pharma Landscape
Major Classes of Plant Drugs
Terpenes and Steroids
Alkaloids and Glycosides
Phenols
Proanthocyanidins
The Emergence of Cannabinoids
Intellectual Property
Production
A New Type of Production: Plant-Made Drugs
Moving Production Forward
Supply and Legal Issues
Drug Development and Manufacture
Chapter 4 Market Breakdown by Technology Type
Sales of Plant-derived Drugs by Region
Plant-derived Drugs by Therapeutic Area
Value of Plant-derived Drugs by Therapeutic Area
A Pipeline Perspective: Composition of Botanical Drugs in Clinical Development
Chapter 5 New Developments and Market Opportunities
Hormone Therapy and Metabolism Applications
Infectious Disease Applications
Pain and Central Nervous System Disease Applications
Cardiovascular and Metabolic Applications
Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Applications
Dermatology Applications
Gastrointestinal Applications
Oncology Applications
Botanical Drugs in Clinical Development
Promising Candidates for Botanical Drugs
Chapter 6 Company Profiles
ABBOTT LABORATORIES
ACORDA THERAPEUTICS INC.
AMAREX CLINICAL RESEARCH
ANALYTICON DISCOVERY GMBH
ARTECEF BV
BAYER HEALTHCARE PHARMACEUTICALS
BIONORICA SE
BIONUMERIK PHARMACEUTICALS INC.
BOEHRINGER INGELHEIM
Pharmaton SA
BRISTOL-MYERS SQUIBB
CARDAX PHARMACEUTICALS
CHI-MED
CHONG KUN DANG PHARMACEUTICAL CORP.
CHUNG MEI BIOPHARMA CO LTD
CURAPHARM INC.
DONG-A-ST
DONGWHA PHARM CO. LTD.
EISAI INC.
EISAI Inc. U.S.
EKOMED LLC
ELI LILLY
FYTOKEM PRODUCTS INC.
GALAPAGOS NV
GLAXOSMITHKLINE
GLENMARK PHARMACEUTICALS LIMITED
GREEN CROSS CORP.
GREEN LABORATORIES LLC
GW PHARMACEUTICALS PLC
HAMIDA PHARMA INC.
HANMI PHARMA CO. LTD.
HETEROGENEITY LLC
HSRX BIOPHARMACEUTICAL
INDENA
INDUS BIOTECH
INMED PHARMACEUTICALS
INSPYR THERAPEUTICS INC.
INSYS THERAPEUTICS INC
IZUN PHARMACEUTICALS CORP.
JOHNSON & JOHNSON
KANGLAITE USA INC.
LANZHOU FOCI PHARMACEUTICALS CO. LTD.
LEO PHARMA
LUPIN PHARMACEUTICALS INC.
MEDIGENE AG
MERCK & CO. INC.
MERLION PHARMACEUTICALS
MICROBIO CO. LTD.
MYCOSYNTHETIX INC.
NAPO PHARMACEUTICALS INC.
NOVARTIS INTERNATIONAL AG
PFIZER
PHARMACEUTICAL PLANT CO.
PHYNOVA
PHYTOMYCO RESEARCH PVT. LTD.
PHYTOPHARMACON INC.
PHYTOQUEST LTD
PIRAMAL PHYTOCARE LTD.
PRAIRIE PLANT SYSTEMS INC.
PRANA THERAPEUTICS
PUNISYN PHARMACEUTICALS LTD. (RIMONEST LTD.)
PURAPHARM INTERNATIONAL LTD.
QUERCEGEN PHARMACEUTICALS LLC
ROTTAPHARM (MADAUS)
SANOFI
SANTALIS PHARMACEUTICALS
Quintis Ltd. (PARENT COMPANY)
SCHWABE PHARMACEUTICALS
SE-CURE PHARMACEUTICALS LTD.
SEQUOIA SCIENCES INC.
SUN PHARMACEUTICAL INDUSTRIES LTD.
SUN TEN PHARMACEUTICAL CO. LTD.
TASLY PHARMACEUTICALS INC.
U.S. Location
TCM BIOTECH INTERNATIONAL CORP.
UNITED CANNABIS CORP.
VALEANT PHARMACEUTICALS INTERNATIONAL INC. (SALIX PHARMACEUTICALS INC.)
Salix Pharmaceuticals
VEDIC LIFESCIENCES PVT. LTD.
YIVIVA
Chapter 7 Appendix
Summary Table : Global Market for Botanical and Plant-derived Drugs*, by Type, Through 2022
Table 1 : Key Events Related to Botanical Medicine
Table 2 : Notable Plant-derived Drugs
Table 3 : Number of Botanicals Pre-INDS and INDs Submitted to the FDA, by Type, Through 2013
Table 4 : SWOT Analysis of Botanical Drug Development
Table 5 : Key Investments in Botanical and Other Plant-derived Drugs
Table 6 : Distinctions Among Products That Use Plants Medicinally
Table 7 : Botanical Composition of Menerba (MF 101)*
Table 8 : Top Pharma Companies, by Revenue, 2016
Table 9 : Major Upcoming U.S. Patent Expiries, 2014-2022
Table 10 : Major Producers of Raw Materials for Plant-Based Medicine
Table 11 : Key Companies with Natural Product Libraries
Table 12 : Number of FDA-Approved Botanical Drugs, Through 2022
Table 13 : Global FDA-Approved Botanical Drugs Market, by Therapeutic Area, Through 2022
Table 14 : Plant-derived Hormone Therapy and Metabolism Drugs in Late-Stage Development
Table 15 : Plant-derived Infectious Disease Drugs in Late-Stage Development
Table 16 : Brain Disorders That are Refractory to Small Molecule Drugs
Table 17 : Plant-derived Pain and CNS Drugs in Late-Stage Development
Table 18 : Plant-derived Cardiovascular and Metabolic Drugs in Late-Stage Development
Table 19 : Plant-Derived Respiratory, Inflammation (Both Nonrelated and Related to Orthopedic) and Autoimmune Drugs in Late-Stage Development
Table 20 : Plant-derived Dermatology/Wound Care Drugs in Late-Stage Development
Table 21 : Plant-derived Gastrointestinal Drugs in Late-Stage Development
Table 22 : Estimated U.S. New Cancer Cases, by Gender, 2016
Table 23 : Plant-derived Oncology Drugs in Late-Stage Development
Table 24 : Botanical Drugs in Clinical Development with Possible FDA-Approved Commercialization, Through 2022
Table 25 : Promising Compounds Being Studied for Medicinal/Therapeutic Potential
Table 26 : Plant-derived Drugs: Their Origin and Actions
Table 27 : Useful Resources for the Botanical Industry
Summary Figure : Global Market for Botanical and Plant-derived Drugs*, by Type, 2016-2022
Figure 1 : Top Therapeutic Areas of FDA Drug Approvals, 2016
Figure 2 : Composition of FDA-Approved Botanical Indications, by Therapeutic Area, 2017 and 2022
Figure 3 : Global FDA-Approved Botanical Drugs Market, by Therapeutic Area, 2017 and 2022
Figure 4 : Therapeutic Areas Targeted for Botanical Drugs in Phase 2 or Later, 2017*

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report